SCHEMBL4667564

SCHEMBL4667564

c1ccc(C(OCCOC(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 3/20 0.65
SCN2A Q99250 3/20 0.65
SCN3A Q9NY46 3/20 0.65
LMNA P02545 2/20 0.65
HTT P42858 2/20 0.65
CHRM2 P08172 2/20 0.65
ADRA2A P08913 2/20 0.65
CHRM1 P11229 2/20 0.65
SLC6A2 P23975 2/20 0.65
SLC6A4 P31645 2/20 0.65
OPRM1 P35372 2/20 0.65
DRD3 P35462 2/20 0.65
SLC6A3 Q01959 2/20 0.65
CYP1A2 P05177 1/20 0.65
CHRM4 P08173 1/20 0.65
CHRM5 P08912 1/20 0.65
CYP2D6 P10635 1/20 0.65
TSHR P16473 1/20 0.65
ADRA2B P18089 1/20 0.65
CHRM3 P20309 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669231 0.90 SLC6A2 (0.61) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL4670218 0.90 SCN1A (0.61) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL14380352 0.89 SCN1A (0.55) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL21382042 0.89 SCN1A (0.55) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL5190981 0.87 CYP3A4 (0.64) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL4669314 0.87 CYP3A4 (0.64) SCN1ASCN2ASCN3ALMNAHTT
Hydrochloric Acid SCHEMBL9721546 0.87 LMNA (0.56) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL4668992 0.87 SCN1A (0.58) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL3336564 0.85 SCN1A (0.57) SCN1ASCN2ASCN3ALMNAHTT
SCHEMBL7962886 0.85 SCN1A (0.57) SCN1ASCN2ASCN3ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
WO-2004028548-A2 INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS CARBOMER, INC. (US) 2004-04-08 WO disclosed
US-20040063612-A1 Neuroprotective agents CARBOMER, INC. 2004-04-01 US disclosed
US-6518314-B1 For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid NYMOX CORPORATION (CA) 2003-02-11 US disclosed
US-6130221-A ALZHEIMERS NYMOX CORPORATION (CA) 2000-10-10 US disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063612-A1 Neuroprotective agents GAP43, NLN, NOS3 SCN1A 703/4885SCN2A 858/4885SCN3A 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.